Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Epidemiology and Surveillance

Efficacy of Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine for Treatment of Uncomplicated Malaria in Children in Zaire and Uíge Provinces, Angola

Mateusz M. Plucinski, Eldin Talundzic, Lindsay Morton, Pedro Rafael Dimbu, Aleixo Panzo Macaia, Filomeno Fortes, Ira Goldman, Naomi Lucchi, Gail Stennies, John R. MacArthur, Venkatachalam Udhayakumar
Mateusz M. Plucinski
aMalaria Branch and President's Malaria Initiative, Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
bEpidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eldin Talundzic
aMalaria Branch and President's Malaria Initiative, Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lindsay Morton
aMalaria Branch and President's Malaria Initiative, Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pedro Rafael Dimbu
cNational Malaria Control Program, Ministry of Health, Luanda, Angola
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aleixo Panzo Macaia
dField Epidemiology and Laboratory Training Program, Ministry of Health, Luanda, Angola
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Filomeno Fortes
cNational Malaria Control Program, Ministry of Health, Luanda, Angola
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ira Goldman
aMalaria Branch and President's Malaria Initiative, Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Naomi Lucchi
aMalaria Branch and President's Malaria Initiative, Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gail Stennies
aMalaria Branch and President's Malaria Initiative, Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John R. MacArthur
aMalaria Branch and President's Malaria Initiative, Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Venkatachalam Udhayakumar
aMalaria Branch and President's Malaria Initiative, Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.04181-14
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Additional Files
  • FIG 1
    • Open in new tab
    • Download powerpoint
    FIG 1

    PCR-uncorrected and PCR-corrected survival functions for time until failure from a 2013 therapeutic efficacy study of AL in Zaire and Uíge Provinces, Angola. DP data are not shown as efficacy was uniformly high.

Tables

  • Figures
  • Additional Files
  • TABLE 1

    Characteristics of patients at enrollment in therapeutic efficacy studies in Zaire and Uíge Provinces, Angola, in 2013

    Parametern (%) in study arm
    ALDP
    ZaireUígeZaireUíge
    Initial screen305188329230
    Slide read287 (94)173 (92)326 (99)222 (97)
    Parasitemia (parasites/ml)
        Negative for plasmodium112 (39)53 (31)174 (53)78 (35)
        Low (<2,000)23 (8.0)10 (5.8)20 (6.1)15 (6.7)
        Target parasitemia (2,000–100,000)102 (36)101 (58)104 (32)102 (46)
        High parasitemia (>100,000)50 (17)9 (5.2)28 (8.6)28 (13)
  • TABLE 2

    Sample size by study arm in therapeutic efficacy studies in Zaire and Uíge Provinces, Angola, in 2013

    Parametern (%) in study arm
    ALDP
    ZaireUígeZaireUíge
    Total enrolled10199102100
    Lost to follow-up11 (11)10 (10)20 (20)9 (9)
    Excluded/censured11 (11)11 (11)2 (2)8 (8)
    Finished study79 (78)78 (79)80 (78)83 (83)
  • TABLE 3

    Response to treatment in therapeutic efficacy studies in Zaire and Uíge Provinces, Angola, in 2013

    ParameterResult in study arm
    ALDP
    Zaire (n = 79)Uíge (n = 78)Zaire (n = 80)Uíge (n = 83)
    ACPR, n (%)61 (77)72 (92)79 (99)83 (100)
    Treatment failure, n (%)18 (23)6 (7.7)1 (1.2)0 (0)
        Early1 (1.3)0 (0)0 (0)0 (0)
        Late17 (22)6 (7.7)1 (1.2)0 (0)
            Day 141 (1.3)0 (0)0 (0)0 (0)
            Day 2110 (13)3 (3.8)0 (0)0 (0)
            Day 286 (7.6)3 (3.8)1 (1.2)0 (0)
        Reinfections10 (13)4 (5.1)1 (1.2)0 (0)
        Recrudescence7 (8.9)2 (2.6)0 (0)0 (0)
        Day 3 clearance, % (95% CI)100 (96–100)97.6 (92–100)100 (96–100)100 (96–100)
    Cumulative success rate on day 28, % (95% CI)
        PCR uncorrected77.4 (69–87)92.3 (87–98)98.8 (96–100)100a
        PCR corrected89.6 (83–97)97.4 (94–100)100a100a
    Proportion of ACPR on day 28, % (95% CI)
        PCR uncorrected77.2 (66–86)92.3 (84–97)98.8 (93–100)100 (96–100)
        PCR corrected88.4 (78–95)97.3 (91–100)100 (95–100)100 (96–100)
    • ↵a Confidence intervals were not calculated for the Kaplan-Meier estimator when the rate was 100%.

  • TABLE 4

    Molecular characteristics of 25 observed treatment failures during therapeutic efficacy studies in Zaire and Uíge Provinces, Angola, in 2013

    Patient ID no.Treatment armaClassificationbMOIcResistance marker(s) on day 0 and day of failured
    pfmdr1eSNPfK13
    CNHaplotypeChr 10Chr 13
    B313gAL-ZETF21NYDwtwtwt
    A111AL-URECR11NFDwtwtwt
    A145AL-URECR11NYDwtwtwt
    B314AL-ZRECR11NYDwtwtwt
    B384AL-ZRECR11NYDwtwtwt
    B385AL-ZRECR21NFDwtwtwt
    B399AL-ZRECR21NFDwtwtwt
    B404AL-ZRECR21NFDwtwtwt
    B416AL-ZRECR21NYDwtwtwt
    B422AL-ZRECR2/11NYD+NFD/NYDwtwtwt
    A114AL-UREIN11NYDwtwtwt
    A115AL-UREIN2/11YFD/YYDwtwtwt
    A144AL-UREIN4/11NYDwtwtwt
    A171AL-UREIN1/21YYD/NFDwtwtwt
    B304AL-ZREIN11NFDwtwtwt
    B312AL-ZREIN11NYDwtwtwt
    B371AL-ZREIN21NFDwtwtwt
    B375AL-ZREIN1/21NFD/YYDwtwtwt
    B386AL-ZREIN11YYY/NYDwtwtwt
    B387AL-ZREIN11NFY/NYDwtwtwt
    B398AL-ZREIN11NYDwtwtwt
    B402AL-ZREIN2/11YYY/NYDwtwtwt
    B421AL-ZREIN1/21NYD/NFDwtwtwt
    B423AL-ZREIN1/21NFD/NYDwtwtwt
    C560DP-ZREIN11YYDwtwtwt
    • ↵a AL, artemether-lumefantrine; DP, dihydroartemisinin-piperaquine; Z, Zaire; U, Uíge.

    • ↵b ETF, early treatment failure; RECR, recrudescence; REIN, reinfection.

    • ↵c Multiplicities of infection (MOI) either are the same for day 0 and the day of failure or are reported as day 0 MOI/day of failure MOI.

    • ↵d Resistance markers either are the same for day 0 and the day of failure or are reported as day 0/day of failure. wt, wild type.

    • ↵e “CN” represents the P. falciparum multidrug resistance gene 1 copy number, and “haplotype” represents the haplotype constructed from mutations N86Y, Y184F, and D1246Y.

    • ↵f Shown are the chromosome 10 (Chr 10) SNP at position 688956 and Chr 13 SNP at position 1718319 associated with artemisinin resistance.

    • ↵g Molecular data for early treatment failure are available for day 0 only.

Additional Files

  • Figures
  • Tables
  • Supplemental material

    Files in this Data Supplement:

    • Supplemental file 1 -

      Additional experimental details and Supplemental Tables S1 to S3.

      PDF, 102K

PreviousNext
Back to top
Download PDF
Citation Tools
Efficacy of Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine for Treatment of Uncomplicated Malaria in Children in Zaire and Uíge Provinces, Angola
Mateusz M. Plucinski, Eldin Talundzic, Lindsay Morton, Pedro Rafael Dimbu, Aleixo Panzo Macaia, Filomeno Fortes, Ira Goldman, Naomi Lucchi, Gail Stennies, John R. MacArthur, Venkatachalam Udhayakumar
Antimicrobial Agents and Chemotherapy Dec 2014, 59 (1) 437-443; DOI: 10.1128/AAC.04181-14

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Efficacy of Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine for Treatment of Uncomplicated Malaria in Children in Zaire and Uíge Provinces, Angola
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Efficacy of Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine for Treatment of Uncomplicated Malaria in Children in Zaire and Uíge Provinces, Angola
Mateusz M. Plucinski, Eldin Talundzic, Lindsay Morton, Pedro Rafael Dimbu, Aleixo Panzo Macaia, Filomeno Fortes, Ira Goldman, Naomi Lucchi, Gail Stennies, John R. MacArthur, Venkatachalam Udhayakumar
Antimicrobial Agents and Chemotherapy Dec 2014, 59 (1) 437-443; DOI: 10.1128/AAC.04181-14
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • INTRODUCTION
    • MATERIALS AND METHODS
    • RESULTS
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596